Impact of Alpha Methyldopa on Angiogenic Factors in Pregnancies with Hypertensive Disorders
Author Information
Author(s): Khalil Asma, Muttukrishna Shanthi, Harrington Kevin, Jauniaux Eric
Primary Institution: The Homerton University Hospital NHS Trust, Queen Mary and Westfield College, University of London
Hypothesis
The study aims to evaluate the impact of antihypertensive therapy with alpha methyldopa on maternal circulating levels and placental production of angiogenic factors in hypertensive disorders of pregnancy.
Conclusion
Alpha methyldopa may specifically affect placental and endothelial cell function in pre-eclampsia patients by altering angiogenic proteins.
Supporting Evidence
- Serum levels of sFlt-1 were significantly higher in women with pre-eclampsia compared to controls.
- Antihypertensive treatment was associated with a significant fall in serum concentrations of sFlt-1 and sEng in women with pre-eclampsia.
- Placental concentrations of sFlt-1 and sEng were significantly higher in women with pre-eclampsia compared to controls.
Takeaway
This study looks at how a medicine called alpha methyldopa helps pregnant women with high blood pressure by changing certain proteins in their blood and placenta.
Methodology
The study measured serum and placental levels of angiogenic factors before and after treatment with alpha methyldopa in women with pre-eclampsia and gestational hypertension.
Limitations
The short time interval (24 to 48 hours) from initiation of treatment to blood sampling limits the understanding of long-term effects.
Participant Demographics
Women with pre-eclampsia, gestational hypertension, and matched normotensive controls.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website